Anixa Biosciences (ANIX) vs Polaryx Therapeutics (PLYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Polaryx Therapeutics is the larger company by market cap ($100.2 million vs $99.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIX | PLYX |
|---|---|---|
| Share price | $2.87 | $2.01 |
| Market cap | $99.60M | $100.19M |
| 1-day change | -1.55% | +0.50% |
| YTD return | -6.73% | — |
| 1-year return | -34.46% | — |
| 5-year return | -33.71% | — |
| EPS (TTM) | $-0.32 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.46 | $48.91 |
| 52-week low | $2.32 | $1.85 |
| Distance from 52-week high | -47.53% | -95.89% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +240.31% | +273.13% |
| Average volume | 302.95K | 76.41K |
| Shares outstanding | 34.76M | 49.85M |
| Employees | 4 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Anixa Biosciences
ANIX stock →Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Polaryx Therapeutics
PLYX stock →Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
ANIX vs PLYX FAQ
Which is bigger, Anixa Biosciences or Polaryx Therapeutics?
Polaryx Therapeutics (PLYX) is larger, with a market capitalization of $100.19M compared with $99.60M for Anixa Biosciences (ANIX).
Are Anixa Biosciences and Polaryx Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.